Status:

RECRUITING

Role of Microbiome in BCG Responsiveness Prediction

Lead Sponsor:

Cédric Poyet

Collaborating Sponsors:

Krebsliga Schweiz

Conditions:

Microbiome

Bladder Cancer

Eligibility:

All Genders

18-90 years

Brief Summary

Our primary aim is to investigate the use of microbial profile from the bladder and the feces of NMIBC patients as a predicting tool for therapy response prior to BCG administration. Our second aim i...

Detailed Description

The microbiome, defined as a characteristic microbial community occupying a reasonably well-defined environment (e.g. gut microbiome), has been increasingly linked with different medical conditions an...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Signed informed consent
  • Ability to understand and follow study procedures and understand informed consent
  • age 18 - 90 years
  • Exclusion Criteria
  • Antibiotic treatment within the last month
  • Immuno-/chemotherapy within the past 6 months
  • Immunosuppressive therapy
  • Major medical, neoplastic (with the exception of skin cancer), surgical or psychiatric condition requiring ongoing management. Minor, well-controlled conditions, such as medically controlled arterial hypertension or occupational asthma, may be present.
  • Additional major diagnosis known to affect the gut or bladder microbiota (e. g. liver cirrhosis, systemic sclerosis, inflammatory bowel disease, inflammatory bowel syndrome, celiac disease, neuropathic bladder)
  • Major past intestinal surgery, especially in small intestine or colon. Cholecystectomy, appendectomy, past perianal surgery or past hernia repair may be present.
  • Major gastrointestinal symptoms (diarrhoea, constipation, abdominal pain, vomiting, unexplained weight loss, rectal bleeding or blood in the stool)
  • Bladder augmentation surgery.
  • Indwelling urinary catheter

Exclusion

    Key Trial Info

    Start Date :

    February 22 2022

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    October 20 2025

    Estimated Enrollment :

    120 Patients enrolled

    Trial Details

    Trial ID

    NCT05204199

    Start Date

    February 22 2022

    End Date

    October 20 2025

    Last Update

    April 5 2024

    Active Locations (5)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (5 locations)

    1

    Kantonsspital Baden

    Baden, Canton of Aargau, Switzerland, 5404

    2

    Spitalzentrum Biel

    Biel/Bienne, Canton of Bern, Switzerland, 2501

    3

    Kantonsspital St. Gallen

    Sankt Gallen, Canton of St. Gallen, Switzerland, 9007

    4

    Kantonsspital Winterthur

    Winterthur, Canton of Zurich, Switzerland, 8401